Cargando…

Plasma amyloid-beta oligomer is related to subjective cognitive decline and brain amyloid status

BACKGROUND: Subjective cognitive decline (SCD) is a target for Alzheimer’s disease prediction. Plasma amyloid-beta oligomer (AβO), the pathogenic form of Aβ in blood, has recently been proposed as a novel blood-based biomarker of AD prediction by representing brain Aβ deposition. The relationship be...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Keun You, Park, Jaesub, Jeong, Yong Hyu, Kim, Hyun Jeong, Lee, Eun, Park, Jin Young, Kim, Eosu, Kim, Woo Jung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9632136/
https://www.ncbi.nlm.nih.gov/pubmed/36324157
http://dx.doi.org/10.1186/s13195-022-01104-6
_version_ 1784823966478630912
author Kim, Keun You
Park, Jaesub
Jeong, Yong Hyu
Kim, Hyun Jeong
Lee, Eun
Park, Jin Young
Kim, Eosu
Kim, Woo Jung
author_facet Kim, Keun You
Park, Jaesub
Jeong, Yong Hyu
Kim, Hyun Jeong
Lee, Eun
Park, Jin Young
Kim, Eosu
Kim, Woo Jung
author_sort Kim, Keun You
collection PubMed
description BACKGROUND: Subjective cognitive decline (SCD) is a target for Alzheimer’s disease prediction. Plasma amyloid-beta oligomer (AβO), the pathogenic form of Aβ in blood, has recently been proposed as a novel blood-based biomarker of AD prediction by representing brain Aβ deposition. The relationship between plasma AβO, brain Aβ deposition, and SCD in individuals with normal objective cognition has not been investigated. METHODS: In this cross-sectional study, we analyzed 126 participants with normal objective cognition. More SCD symptoms were expressed as higher scores of the Subjective Cognitive Decline Questionnaire (SCDQ) and Memory Age-associated Complaint Questionnaire (MACQ). The plasma AβO level of each participant was measured twice for validation and expressed as a concentration (ng/mL) and a ratio relative to the mean value of two internal standards. Brain Aβ deposition was assessed by [(18)F] flutemetamol positron emission tomography (PET) and expressed as standard uptake value ratio (SUVR). Associations of SCDQ and MACQ with plasma AβO levels or SUVR were analyzed in multiple linear regression models. The association between plasma AβO level and flutemetamol PET positivity was assessed in logistic regression and receiver operative characteristic analyses. RESULTS: Overall, participants were 73.3 years old with female predominance (69.0%). After adjustment for confounders, high SCDQ and MACQ scores were associated with the high plasma AβO levels as both concentrations and ratios (ratios: standardized coefficient = 0.246 and p = 0.023 for SCDQ, standardized coefficient = 0.209 and p = 0.029 for MACQ; concentrations: standardized coefficient = 0.257 and p = 0.015 for SCDQ, standardized coefficient = 0.217 and p = 0.021 for MACQ). In contrast, SCDQ and MACQ were not significantly associated with SUVRs (p = 0.134 for SCDQ, p = 0.079 for MACQ). High plasma AβO levels were associated with flutemetamol PET (+) with an area under the curve of 0.694 (ratio) or 0.662 (concentration). Combined with APOE e4, plasma AβO presented area under the curves of 0.789 (ratio) and 0.783 (concentration). CONCLUSIONS: Our findings indicate that the high plasma AβO level could serve as a potential surrogate biomarker of severe SCD and the presence of brain Aβ deposition in individuals with normal objective cognition.
format Online
Article
Text
id pubmed-9632136
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-96321362022-11-04 Plasma amyloid-beta oligomer is related to subjective cognitive decline and brain amyloid status Kim, Keun You Park, Jaesub Jeong, Yong Hyu Kim, Hyun Jeong Lee, Eun Park, Jin Young Kim, Eosu Kim, Woo Jung Alzheimers Res Ther Research BACKGROUND: Subjective cognitive decline (SCD) is a target for Alzheimer’s disease prediction. Plasma amyloid-beta oligomer (AβO), the pathogenic form of Aβ in blood, has recently been proposed as a novel blood-based biomarker of AD prediction by representing brain Aβ deposition. The relationship between plasma AβO, brain Aβ deposition, and SCD in individuals with normal objective cognition has not been investigated. METHODS: In this cross-sectional study, we analyzed 126 participants with normal objective cognition. More SCD symptoms were expressed as higher scores of the Subjective Cognitive Decline Questionnaire (SCDQ) and Memory Age-associated Complaint Questionnaire (MACQ). The plasma AβO level of each participant was measured twice for validation and expressed as a concentration (ng/mL) and a ratio relative to the mean value of two internal standards. Brain Aβ deposition was assessed by [(18)F] flutemetamol positron emission tomography (PET) and expressed as standard uptake value ratio (SUVR). Associations of SCDQ and MACQ with plasma AβO levels or SUVR were analyzed in multiple linear regression models. The association between plasma AβO level and flutemetamol PET positivity was assessed in logistic regression and receiver operative characteristic analyses. RESULTS: Overall, participants were 73.3 years old with female predominance (69.0%). After adjustment for confounders, high SCDQ and MACQ scores were associated with the high plasma AβO levels as both concentrations and ratios (ratios: standardized coefficient = 0.246 and p = 0.023 for SCDQ, standardized coefficient = 0.209 and p = 0.029 for MACQ; concentrations: standardized coefficient = 0.257 and p = 0.015 for SCDQ, standardized coefficient = 0.217 and p = 0.021 for MACQ). In contrast, SCDQ and MACQ were not significantly associated with SUVRs (p = 0.134 for SCDQ, p = 0.079 for MACQ). High plasma AβO levels were associated with flutemetamol PET (+) with an area under the curve of 0.694 (ratio) or 0.662 (concentration). Combined with APOE e4, plasma AβO presented area under the curves of 0.789 (ratio) and 0.783 (concentration). CONCLUSIONS: Our findings indicate that the high plasma AβO level could serve as a potential surrogate biomarker of severe SCD and the presence of brain Aβ deposition in individuals with normal objective cognition. BioMed Central 2022-11-03 /pmc/articles/PMC9632136/ /pubmed/36324157 http://dx.doi.org/10.1186/s13195-022-01104-6 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Kim, Keun You
Park, Jaesub
Jeong, Yong Hyu
Kim, Hyun Jeong
Lee, Eun
Park, Jin Young
Kim, Eosu
Kim, Woo Jung
Plasma amyloid-beta oligomer is related to subjective cognitive decline and brain amyloid status
title Plasma amyloid-beta oligomer is related to subjective cognitive decline and brain amyloid status
title_full Plasma amyloid-beta oligomer is related to subjective cognitive decline and brain amyloid status
title_fullStr Plasma amyloid-beta oligomer is related to subjective cognitive decline and brain amyloid status
title_full_unstemmed Plasma amyloid-beta oligomer is related to subjective cognitive decline and brain amyloid status
title_short Plasma amyloid-beta oligomer is related to subjective cognitive decline and brain amyloid status
title_sort plasma amyloid-beta oligomer is related to subjective cognitive decline and brain amyloid status
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9632136/
https://www.ncbi.nlm.nih.gov/pubmed/36324157
http://dx.doi.org/10.1186/s13195-022-01104-6
work_keys_str_mv AT kimkeunyou plasmaamyloidbetaoligomerisrelatedtosubjectivecognitivedeclineandbrainamyloidstatus
AT parkjaesub plasmaamyloidbetaoligomerisrelatedtosubjectivecognitivedeclineandbrainamyloidstatus
AT jeongyonghyu plasmaamyloidbetaoligomerisrelatedtosubjectivecognitivedeclineandbrainamyloidstatus
AT kimhyunjeong plasmaamyloidbetaoligomerisrelatedtosubjectivecognitivedeclineandbrainamyloidstatus
AT leeeun plasmaamyloidbetaoligomerisrelatedtosubjectivecognitivedeclineandbrainamyloidstatus
AT parkjinyoung plasmaamyloidbetaoligomerisrelatedtosubjectivecognitivedeclineandbrainamyloidstatus
AT kimeosu plasmaamyloidbetaoligomerisrelatedtosubjectivecognitivedeclineandbrainamyloidstatus
AT kimwoojung plasmaamyloidbetaoligomerisrelatedtosubjectivecognitivedeclineandbrainamyloidstatus